Study Links Biological Age to Dementia Risk

A recent study by the Alzheimer’s Association examined the connection between biological age and dementia risk. Researchers in the U.K. used data from over 223,000 UK Biobank participants to explore this link, focusing on blood metabolites, which relate to fat processing, inflammation, and energy utilization.

The study revealed that nearly 4,000 participants developed dementia over the course of the follow-up period. To assess the risk, researchers introduced the MileAge delta. This measure is the difference between metabolite-predicted age and actual age. A higher MileAge delta indicates a person’s biological age is older than expected, correlating with an increased risk of various types of dementia.

The strongest association was found with vascular dementia, the second most prevalent dementia type.

Individuals with a high MileAge delta and carrying the APOE gene linked to Alzheimer’s faced a tenfold increase in all-cause dementia risk. The study emphasized the connection between genetic factors and biological aging in predicting dementia.

Dr. Julian Mutz, a co-author and research fellow at King’s College London, highlighted the significance of these findings. He stressed the need to examine both genetic and other risk factors, which could inform strategies to reduce dementia risks.

Dr. Marc Siegel, a senior medical analyst, pointed out the study’s implications for understanding the practical aspects of healthspan versus lifespan. He emphasized the role of the APOE gene in provoking dementia, especially Alzheimer’s, and how chronic health conditions can escalate the risk if combined with this gene. The study showed a 60% increased risk of vascular dementia with associated poor health conditions like heart disease, high blood pressure, and obesity.

The researchers noted the study’s observational nature, which means it couldn’t establish causality between biological age and dementia risk. Additionally, the reliance on a single blood measurement and the homogeneous UK Biobank sample limited the study’s generalizability across diverse populations. Further validation of the MileAge biomarker is essential before its clinical application.